// App-Quantinova.ai

: Effect of Siponimod on Disability Progression as Measured by the Ambulation Score a Subscore of the Neurostatus EDSS Post hoc Analysis of the EXPAND Trial in SPMS

Researchers

Presenter

  • Marcus DSouza

Principal Investigators

  • Gavin Giovannoni

  • Patrick Vermersch

  • Jeff Maca

  • Soudeh Ansari

  • Goeril Karlsson

  • Daniela Piani-Meier

  • Ludwig Kappos

Medical Centers

  • *(equal contribution) Neurologic Clinic and Policlinic, Department of Head, Spine and Neuromedicine, University Hospital of Basel, Basel, Switzerland

  • Research Center for Clinical Neuroimmunology and Neuroscience Basel (RCNB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

  • Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

  • University Lille, INSERM U, CHU Lille, FHU Precise, Lille, France

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceuticals Corporation, Cambridge, MA

  • Novartis AG, Basel, Switzerland

Locations

  • Switzerland

  • United Kingdom

  • France

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Siponimod

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved